Paratek Pharmaceuticals, Inc. reiterated earnings guidance for the year 2023. For the year, the company expects revenue guidance announced earlier this year, which is expected to be in the range of $143 to $158 million, which includes the following components: UZYRA nenet U.S. sales of approximately $125 to $135 million. BARDA government contract svice and grantnt revenue between $15 to $20 million.

Royalty and collaboration revenue of approximately $3 million.